<DOC>
	<DOCNO>NCT00004218</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . It yet know regimen chemotherapy effective chronic lymphocytic leukemia . PURPOSE : This randomized phase III trial study chlorambucil see well work compare fludarabine cyclophosphamide fludarabine alone treat patient newly diagnose chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Chemotherapy Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Compare survival rate patient newly diagnose chronic lymphocytic leukemia treat chlorambucil alone vs fludarabine without cyclophosphamide . - Compare response rate duration remission patient treat regimen . - Compare toxic effect regimens patient . - Compare quality life patient treat regimen . - Determine impact drug response information provide DiSC assay response rate survival relapse nonresponding patient . - Assess prognostic value five genetic marker : trisomy 12 deletion 11q23 , 13q14 , p53 , 6q21 patient treated regimen . OUTLINE : This randomize study . Patients enter one three treatment arm first randomization . Depending response , patient may also participate second randomization one two treatment arm . - First randomization : - Arm I : Patients receive oral chlorambucil daily 7 day . Treatment repeat every 4 week maximum response 1 year . - Arm II : Patients receive fludarabine IV orally daily 5 day . Treatment repeat every 4 week 3-8 course . - Arm III : Patients receive cyclophosphamide IV fludarabine IV 3 day orally daily 5 day . Treatment repeat every 4 week 3-8 course . Patients relapse remission least 1 year may repeat initial therapy may participate second randomization . Patients experience progressive disease relapse within 1 year treatment proceed second randomization . - Second randomization : - Arm I : Treatment guide result DiSC assay . Treatment may one first-line treatment fludarabine standard CHOP chemotherapy repeat every 4 week ( cyclophosphamide IV , doxorubicin IV , vincristine IV , oral prednisolone day 1-5 ) therapy guide result DiSC assay . - Arm II : Treatment physician 's choice , may include option arm I . Quality life assess prior initial therapy ; 3 , 6 , 12 month ; annually thereafter . Patients follow annually survival . PROJECTED ACCRUAL : A total 750 patient accrue study within 6-7 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis Bcell chronic lymphocytic leukemia ( CLL ) require therapy meeting follow criterion : Previously untreated disease Peripheral blood morphology , exclude leukemia lowgrade lymphoma leukemic phase Cell marker : CD5+ , CD23+ , SmIg ( weak ) , CD79b , FMC7 Persistent lymphocytosis ( great 10,000/mm^3 ) At least 40 % bone marrow infiltration Stage 0 I progressive disease indicate least one following : Persistent rise lymphocyte count double time le 12 month Downward trend hemoglobin and/or platelet count At least 50 % increase size liver and/or spleen and/or lymph node Appearance lymphadenopathy , hepatomegaly , splenomegaly Constitutional symptom cause disease Pyrexia Night sweat Weight loss OR Stage II III PATIENT CHARACTERISTICS : Age : Not specify Performance status : Not specify Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) * SGOT/SGPT great 2 time ULN* NOTE : * Unless due CLL Renal : Creatinine clearance least 30 mL/min Other : No cancer lifethreatening disease Not pregnant Fertile patient must use effective contraception 6 month study therapy PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy No concurrent corticosteroid ( e.g. , dexamethasone ) antiemetic Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>stage 0 chronic lymphocytic leukemia</keyword>
</DOC>